ArticleWorld journal of urology2026
Single-port robotic radical prostatectomy: early results from a UK centre.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProstate cancer is the most common cancer affecting men in the United Kingdom. Single-port robot-assisted radical prostatectomy (SP-RARP) is one of the latest evolutions in the realm of minimally invasive surgery for prostate cancer. We aim to describe our institution's initial experience with single-port robot-assisted radical prostatectomy. SUBJECTS AND
methodsWe retrospectively reviewed all the electronic theatre records to identify all patients undergoing Single-port robot-assisted radical prostatectomy. All cases were performed using the da Vinci SP Surgical System from September 2024 to December 2025. This review was registered and carried out in line with the Trust's audit & research guidelines.
resultsA total of 50 patients underwent SP-RARP. The median patient age was 61 years, with a mean BMI of 27 kg/m² and an ASA grade distribution of 1-3. The median operative time was 120 min (86-180), and the median estimated blood loss was 100 mL (20-400). No intra-operative complications were recorded. Nerve-sparing was performed bilaterally in 25 patients, unilaterally in 22, and was not performed in 3 cases. The median initial post-operative pain score was 0.9, and the median length of stay was 1 day. At three months, 68% of patients were fully continent, and 75% achieved erectile function sufficient for intercourse with phosphodiesterase-5 inhibitors with or without vacuum device support. Final pathological staging showed pT2b disease in 3 patients, pT2c in 23, pT3a in 23, and pT3b in 1. A positive surgical margin greater than 3 mm was identified in one patient.
conclusionThis represents the first UK case series of SP-RARP. Early outcomes demonstrate the procedure to be feasible and safe, with operative, oncological, and functional results comparable to published international SP-RARP data. These findings support the need for further comparative studies against multi-port RARP to better define the relative advantages of the single-port platform.
Indexed as
Identifiers
42307697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.